Bondinell, William E; Ku, Thomas W; Neeb, Michael J;

Compounds and methods

This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptior. In addition, this invention relates to the treatment and prevention of disease states mediatd by CCR5.

• Oscillating toothbrush Recoverable article
• Microemulsion fuel system Nozzle assembly
• Apparatus for body panel attachment Medieval castle board game
• Process for realuminating zeolites Motor vehicle front end protector
• Accessory brush attachment Free pivot-arm key plate
• Tubular microwave phase shifter Formation of conductive rugged silicon
• Cladding layer Signal sampling gate circuit
• Plaque cracker Multipin connector
• Roll nip arrangement Photographic copying machine
• Electrodeionization method Guanfacine in treating opiate addiction
• Dust collecting work station Asynchronous digital circuit testing system
• Softball Method of forming a capacitor
• Document stacking Semiconductor assembly encapsulation mold
• Process for preparing organotin compounds Juvenile safety car seat
• Ski boot key Cooling system for HTS machines
• Automatic sample testing machine Distance measuring arrangement
• TRAF inhibitors Detection of fuel rod leakage
• Container Leaded chip carrier
• Folding shelving Tree implant device
• Process for regenerating corn Organ visualization
• Game and cruciform game table Multiple symbol differential detection
• Ethylene polymerization catalyst and method

What is claimed is:

1. A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound which is N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-be nzopyran-3-carboxamide or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the CCR5-mediated disease state is an inflammatory disease.

3. The method of claim 1, wherein the CCR5-mediated disease state is an atopic disorder.

4. The method of claim 1, wherein the CCR5-mediated disease state is an autoimmune disorder.

5. A compound which is N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-be nzopyran-3-carboxamide.